Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology

GlobeNewswireApr 17 05:00

Cingulate Inc (CING) Receives a Hold From Maxim Group

TipRanksApr 4 23:05

Cingulate Reports Q4 Results

Seeking AlphaApr 1 22:12

Cingulate Had $52,416 in Cash and Cash Equivalent at Dec 31 >CINGW

Cingulate Had $52,416 in Cash and Cash Equivalent at Dec 31 >CINGW

Dow JonesApr 1 20:06

Cingulate 4Q Loss $6.93M >CINGW

Cingulate 4Q Loss $6.93M >CINGW

Dow JonesApr 1 20:05

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update.

GlobeNewswireApr 1 20:00